HeartBeam (BEAT) risk factors, FY2024 10-K

Risks Related to Our Business

1. 01We require additional capital to support our present business plan and our anticipated business growth, and such capital may not be available on acceptable terms, or at all, which would adversely affect our ability to operate
2. 02We cannot predict our future capital needs and we may not be able to secure additional financing
3. 03We have a limited operating history upon which investors can evaluate our future prospects
4. 04Management and our independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern
5. 05We have no revenues and we cannot predict when we will achieve first revenues and sustained profitability
6. 06We may never complete the development and commercialization of products that we are currently developing and future development of new generations of any of our other proposed products
7. 07We may not meet our product development and commercialization milestones
8. 08Our business is dependent upon physicians utilizing and prescribing our solution; if we fail to engage physicians to utilize our solution, our revenues may never materialize or may not meet our projections
9. 09We are subject to extensive governmental regulations relating to the manufacturing, labeling, and marketing of our products
10. 10If we are not able to both obtain and maintain adequate levels of third-party reimbursement for our products, it would have a material adverse effect on our business
11. 11Changes in reimbursement practices of third-party payers could affect the demand for our products and services and our revenue levels
12. 12We may experience difficulty in obtaining reimbursement for our services from commercial payors that consider our technology to be experimental and investigational, which would adversely affect our revenue and operating results
13. 13Reimbursement by Medicare is highly regulated and subject to change; our failure to comply with applicable regulations could decrease our expected revenue and may subject us to penalties or have an adverse impact on our business
14. 14Consolidation of commercial payors could result in payors eliminating coverage of mobile cardiac monitoring solutions or reducing reimbursement rates
15. 15Product defects could adversely affect the results of our operations
16. 16Interruptions or delays in telecommunications systems or in the data services provided to us by cellular communication providers or the loss of our wireless or data services could impair the delivery of our cardiac monitoring services
17. 17Interruptions in computing and data management cloud systems could impair the delivery of our cardiac monitoring services
18. 18We could be exposed to significant liability claims if we are unable to obtain insurance at acceptable costs and adequate levels or otherwise protect ourselves against potential product liability claims
19. 19The results of our research and development efforts are uncertain and there can be no assurance of the commercial success of our products
20. 20If we fail to retain certain of our key personnel and attract and retain additional qualified personnel, we might not be able to pursue our growth strategy
21. 21We will not be profitable unless we can demonstrate that our products can be manufactured at low prices
22. 22Our dependence on a limited number of suppliers may prevent us from delivering our devices on a timely basis
23. 23We rely significantly on information technology and any failure, inadequacy, or security lapse of that technology, including any cybersecurity incidents, could harm us
24. 24We cannot provide assurances that in the future there will be no weaknesses in our internal controls and that they will be effectively remediated if any were to occur in the future

Risks Related to Economic Conditions

1. 25We maintain our cash at financial institutions, often in balances that exceed federally insured limits
2. 26Changes in tax laws or regulations may increase tax uncertainty and adversely affect results of our operations and our effective tax rate
3. 27Escalating global trade tensions, the Russia and Ukraine war, the Israel-Hamas war, the adoption or expansion of tariffs and trade restrictions and economic disruption and uncertainty resulting therefrom could negatively impact us
4. 28Natural disasters and other events beyond our control could materially adversely affect us
5. 29Our business and operations, and the operations of our suppliers and customers, have been, and may in the future be adversely affected by epidemics, pandemics or other public health crises such as the COVID-19 pandemic outbreak

Risks Related to Our Industry

1. 30The industry in which we operate is highly competitive and subject to rapid technological change. If our competitors are better able to develop and market products that are safer, more effective, less costly, easier to use, or are otherwise more attractive, we may be unable to compete effectively with other companies
2. 31We face competition from other medical device companies that focus on similar markets
3. 32Unsuccessful clinical trials or procedures relating to products under development could have a material adverse effect on our prospects
4. 33Intellectual property litigation and infringement claims could cause us to incur significant expenses or prevent us from selling certain of our products
5. 34If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
6. 35If we are unable to protect our proprietary rights, or if we infringe on the proprietary rights of others, our competitiveness and business prospects may be materially damaged
7. 36Dependence on our proprietary rights and failing to protect such rights or to be successful in litigation related to such rights may result in our payment of significant monetary damages or impact offerings in our product portfolios
8. 37Enforcement of federal and state laws regarding privacy and security of patient information may adversely affect our business, financial condition or operations
9. 38We may become subject, directly or indirectly, to federal and state health care fraud and abuse laws and regulations and if we are unable to fully comply with such laws, the Company could face substantial penalties
10. 39We may be subject to federal and state false claims laws which impose substantial penalties

Risks Related To Common Stock

1. 40The price of our Common Stock and Warrants may be subject to wide fluctuations
2. 41We are an “emerging growth company,” and any decision on our part to comply with certain reduced disclosure requirements
3. 42We are a smaller reporting company, and we cannot be certain if the reduced reporting requirements applicable to smaller reporting companies will make our common stock less attractive to investors
4. 43Future sales and issuances of our Common Stock or rights to purchase Common Stock, including pursuant to our equity incentive plans and other equity securities could result in dilution of the percentage ownership of our stockholders and could cause our stock price to fall
5. 44Nasdaq Capital Market, may delist our Common Stock if we fail to comply with ongoing listing standards
6. 45If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline
7. 46Our cash requirements may vary from those now planned depending upon numerous factors, including the result of future research and development activities, our ability to estimate future expenses and acceptance of our products in the market
8. 47If our shares become subject to the penny stock rules, it would become more difficult to trade our shares
9. 48Liability of directors for breach of duty is limited under Delaware law
10. 49These limitations of liability do not apply to liabilities arising under the federal or state securities laws and do not affect the availability of equitable remedies such as injunctive relief or rescission
11. 50We do not anticipate paying any cash dividends on our Common Stock in the foreseeable future and, as such, capital appreciation, if any, of our Common Stock will be your sole source of gain for the foreseeable future